CD20 Cytoplasmic, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD20 Cytoplasmic, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD20 Cytoplasmic, Human |
| Clone | REAL649 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | n/a |
| Format | phycoerythrin (PE) conjugate |
| Size | 200 µL |
| Concentration | n/a |
| Applications | MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD20 Cytoplasmic Antibody, anti-human, PE, REAdye_lease™. Clone REAL649 is an antibody fragment derived from the full CD20 Cytoplasmic antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity. | Clone REAL649 recognizes an intracytoplasmic epitope localized on the CD20 antigen, which is a non-glycosylated transmembrane protein of 33-37 kDa that is expressed on B lineage cells from the pre-B cell stage to the B cell lymphoblast stage. The antigen is also expressed on most malignant B cells. CD20 is not found on early B cell progenitors or plasma cells. Oligomers of CD20 form a Ca2+ channel and might function in the regulation of local responses during B cell activation. In vitro effects of CD20-specific antibodies on resting B cells indicate that CD20 is able to transduce an extracellular signal affecting the G0/G1 cell cycle transition. Studies have demonstrated that CD20-initiated intracellular signals involve tyrosine kinase activation and that CD20 is tightly associated with both serine and tyrosine kinases. | For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675). | |
| Immunogen | n/a |
| Other Names | CD20cy, CD20 cytoplasmic domain |
| Gene, Accession # | n/a |
| Catalog # | 130-123-084 |
| Price | $490 |
| Order / More Info | CD20 Cytoplasmic, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Einfeld, D. A. et al. (1988) Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 7 (3): 711-717. | Deans, J. P. et al. (1995) Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J. Biol. Chem. 270 (38): 22632-22638. | Vaughan, A. T. et al. (2015) Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain. J. Biol. Chem. 290 (9): 5424-5437. | Shanehbandi, D. et al. (2017) CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies. Curr. Cancer Drug Targets 17 (5): 423-444. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies